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Abstract 
Both cardiac and peripheral vasculature dysfunction likely contribute, in part, to 
elevations in TNF-α and exercise intolerance in chronic heart failure (CHF). The pharmaceutical 
TNF-α synthesis suppressor pentoxifylline (PTX) reduces plasma [TNF-α] and improves left 
ventricular (LV) function in CHF rats, but the effects of PTX on skeletal muscle blood flow (BF) 
and vascular conductance (VC) during exercise are unknown. We tested the hypothesis that PTX 
would elevate skeletal muscle BF and VC at rest and during submaximal treadmill exercise in 
CHF rats (coronary artery ligation).  CHF rats received i.p. injections of 30 mg·kg
-1
·day
-1
 of PTX 
(CHF+PTX, n=13) or saline (CHF, n=8) for 21 days.  Mean arterial pressure (MAP) and BF 
(radiolabeled microsphere infusions) were measured at rest and during treadmill exercise (20 
m/min, 5% grade). Myocardial infarct (MI) size was not different between groups (CHF: 37±4, 
CHF+PTX: 37±3% of LV wall; p>0.05).  Resting and exercising MAP was greater in CHF+PTX 
compared to CHF (p<0.05 for both).  At rest, total hindlimb skeletal muscle BF and VC were not 
different between groups (p>0.05).  However, during exercise PTX increased total hindlimb BF 
(CHF: 83±9, CHF+PTX: 114±8 ml·min
-1
·100g
-1
, p<0.05) and VC (CHF: 0.75±0.08, CHF+PTX: 
0.88±0.06 ml·min
-1
·100g
-1
·mmHg
-1
, p<0.05).  Furthermore, exercising BF was increased in 21, 
and VC in 11, of the 28 individual hindlimb muscles or muscle parts with no apparent fiber-type 
specificity.  Thus, PTX administration augments skeletal muscle BF and VC during locomotory 
exercise in CHF rats, which carries important therapeutic implications for CHF patients. 
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Chapter 1 - Introduction 
Chronic heart failure (CHF) is a multifaceted clinical disorder hallmarked by left 
ventricular (LV) dysfunction and cardiac output insufficiency.  Reductions in cardiac output 
prompt an exaggeration in sympathetic nervous system activity, which initially attempts to 
maintain arterial blood pressure but precipitates progressive multiple-organ system dysfunction 
and impaired peripheral oxygen (O2) transport (Reviewed by Poole et al., 2012).  Specifically, 
CHF results in enhanced sympathetically-mediated vasoconstriction and reduced peripheral 
vasomotor control which alters the spatial (Musch & Terrell, 1992; Miyazaki et al, 2007) and 
temporal (Richardson et al., 2003) matching of skeletal muscle O2 delivery relative to O2 
demand during exercise.  Impairments in peripheral O2 transport lead to exercise intolerance and 
a reduced quality of life. 
 One potential mediator of the impaired O2 transport in CHF patients is elevation of the 
pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α). TNF-α is elevated in both 
cachectic and non-cachectic CHF patients and plasma TNF-α concentration ([TNF-α]) correlates 
positively with disease severity thereby constituting a powerful prognostic indicator (Levine et 
al., 1990; Milani et al., 1996). Elevations of TNF-α in autonomic regulatory regions of the brain 
result in sympathoexcitation via alterations in superoxide and nitric oxide (NO)-mediated 
signaling in CHF (Guggilam et al., 2011). In the heart, TNF-α up regulates inducible NO 
synthase (iNOS), induces negative inotropic effects and reduces cardiac myocyte contractility 
(Finkel et al., 1992; Balligand et al., 1993).  In the periphery, TNF-α, in conjunction with 
interleukin-1 (IL-1), increases expression of adhesive molecules and associated receptors on 
vascular endothelial cells (Reviewed by Ceconi et al., 1998) and contributes to impaired skeletal 
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muscle structure and function through promotion of catabolism and inhibition of contractile 
function (Li et al., 2001).   
Given the negative cardiovascular effects of TNF-α in CHF, the phosphodiesterase 
inhibitor pentoxifylline (PTX) represents a powerful therapeutic strategy based on its ability to 
down regulate TNF-α gene transcription and suppress TNF-α synthesis (Doherty et al., 1991).  In 
a clinical setting, PTX administration in CHF patients improved LV ejection fraction and New 
York Heart Association (NYHA) functional classification due, at least in part, to reductions in 
plasma [TNF-α] in addition to increased exercise capacity (Sliwa et al., 2004). In CHF rats, PTX 
administration also reduces [TNF-α] and improves LV function as evidenced by reductions in 
LV end-diastolic pressure (LVEDP; Guggilam et al., 2008).  In addition, PTX administration 
lowers circulating levels of norepinephrine and epinephrine and attenuates renal sympathetic 
nerve activity (Guggilam et al., 2007). However, whether PTX-induced improvements in LV 
function and reductions in sympathoexcitation translate to increases in blood flow (BF) within 
and among active skeletal muscle during exercise in CHF subjects remains unknown.  This is 
crucial information given that improvements in BF and O2 delivery during exercise may improve 
exercise capacity and quality of life in CHF patients.  
The purpose of the present investigation was to determine the effects of chronic PTX 
administration on active skeletal muscle BF distribution during locomotory exercise in CHF. 
Specifically, we tested the hypothesis that 21 days of PTX administration in CHF rats would 
elevate hindlimb skeletal muscle blood flow and vascular conductance (VC) during submaximal 
treadmill running. 
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Chapter 2 - Literature Review 
Recent medical advances now allow individuals to survive a cardiovascular event, 
however many experience reduced quality of life after recovery. These advancements have 
contributed to an increased incidence and prevalence of individuals living with cardiovascular 
disease and heart failure (Antunes-Correa et al., 2011).  There has been a call to action for health 
professionals to investigate recovery, rehabilitation, and treatment options for heart disease and 
CHF patients. 
 CHF and Exercise Intolerance 
The cardiovascular system has crucial decisions to make about how to distribute cardiac 
output to various organs and tissues in the body. Interaction between the sympathetic nervous 
system and locally mediated muscle and tissue vasodilation plays an important role in this 
distribution, and these two systems work together to deliver adequate BF to active and inactive 
tissues while maintaining mean arterial pressure (MAP; DiCarlo et al., 1996).  CHF is a complex 
clinical disorder with the core perturbation being central cardiac dysfunction, specifically 
reduced cardiac output. Sympathetic nerve activity is upregulated as a part of the body’s 
response to the reductions in cardiac output caused by myocardial damage. While it initially 
serves to maintain cardiac output, chronic sympathetic activation contributes to a cascade of 
organ and tissue dysfunction throughout the body (Reviewed by Poole et al., 2012). 
Additionally, the NO pathway, a major contributor to skeletal muscle vasodilation, is also 
impaired in CHF (Hirai et al., 1995).  
Patients with CHF experience reduced maximal oxygen uptake and exercise capacity, and 
experience rapid fatigue when completing activities of daily living (Marcinkiewicz et al., 2000; 
Antunes-Correa et al., 2011).  These deleterious effects are the result of reduced skeletal muscle 
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BF, O2 transport, and NO bioavailability (Reviewed by Poole et al., 2012). Reductions in 
skeletal muscle BF affect the body’s ability to meet the O2 demand of the working muscle.  This 
is due in part to slower O2 uptake kinetics and an impaired O2 diffusion capacity (Richardson et 
al., 2003).  Additionally, reductions in skeletal muscle BF appear to be fiber-type dependent, 
given that O2 transport and microvascular O2 pressure recovery to slow-twitch muscle fibers is 
selectively reduced (Hirai et al., 1995; McDonough et al., 2004).  Slow twitch muscle fibers are 
responsible for many of the activities of daily living, explaining the decreased exercise capacity 
and rapid fatigue experienced by patients with CHF (McDonough et al., 2004). 
 Immune Activation in CHF 
CHF is associated with immune system activation, which includes elevated circulating 
pro-inflammatory cytokines, specifically plasma TNF-α (Levine et al., 1990).  TNF-α is secreted 
by macrophages as an immune response mediating the effects of a physiologic disturbance, (in 
CHF, ischemia in cardiac muscle tissue), furthering the inflammatory response (Doherty et al., 
1991).  Circulating concentrations of pro-inflammatory cytokines are correlated with severity of 
disease, making them important prognostic indicators (Levine et al., 1990).  
Elevated [TNF-α] facilitates functional derangement in CHF via perturbations in 
sympathetic nerve activity, cardiac muscle tissue, and peripheral vascular control. Guggilam et 
al. (2011) determined that TNF-α upregulation in autonomic regulatory regions of the brain, 
including the hypothalamus and paraventricular nucleus, contributes to sympathoexcitation in 
CHF due to alterations in NO-mediated signaling.  TNF-α expression is also elevated in cardiac 
tissue, which leads to reductions in cardiac myocyte contractility via upregulatin of iNOS 
(Balligand et al., 1993; Finkel et al., 1992). Endothelial dysfunction including increased 
adhesive molecule expression (Reviewed by Ceconi et al., 1998) and impaired skeletal muscle 
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structure and function (Li et al., 2001) is another result of TNF-α upregulation in CHF ultimately 
affecting exercise tolerance and quality of life in these patients. 
 TNF-α: Effects of Direct Inhibition 
Etanercept is a soluble recombinant TNF-α antagonist that inactivates TNF-α when 
binding, thus preventing TNF-α from binding with its cell membrane receptor (Mann et al., 
2004). Due to the negative impact immune activation and elevated pro-inflammatory cytokines 
have in CHF a clinical trial was conducted to investigate the effects of TNF-α receptor inhibition 
in CHF patients using etanercept.  It was thought that blocking the action of TNF-α would 
improve functional status of CHF patients, however the study was terminated early due to lack of 
benefits seen in the participants.  The exact mechanism for this lack of improvement, and in 
certain cases worsening of functional status, is not known. Nevertheless this study demonstrates 
that inhibition of TNF-α at the receptor site is ineffective in the condition of heart failure. 
 Effects of Pentoxifylline (PTX) Administration 
PTX is a methyl-xanthine derivative and a competitive non-specific phosphodiesterase 
inhibitor used regularly in the treatment of peripheral vascular disease because of it vasodilatory 
affects in the vasculature (McNamara et al., 1998). PTX has also been shown to downregulate 
TNF-α synthesis via downregulation of TNF-α gene transcription.  Importantly, PTX also 
attenuates circulating plasma [IL-12], [catecholamine], [C-reactive protein] as well as other pro-
inflammatory cytokines in CHF (Guggilam et al., 2007; 2008; Reviewed by Shaw et al., 2009).   
Guggilam et al. investigated the link between immune activation and neurohumoral 
excitation in CHF employing PTX (2007; 2008).  In this study CHF rats were treated with either 
PTX or a vehicle for 5 weeks.  CHF rats had a reduced left ventricular function compared to that 
of healthy rats prior to treatment; however, treatment with PTX prevented further decline in 
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cardiac pump function in the CHF rats. Plasma [TNF-α] and [catecholamine] in the PTX-treated 
group were reduced to values near that of the healthy rats (Guggilam et al., 2007). Additionally 
PTX administration also resulted in reduced renal sympathetic nerve activity and Nox2 
expression in the CHF rats (Guggilam et al., 2007).  This study demonstrates the role pro-
inflammatory cytokines play in the sympathoexcitation apparent in CHF, and the important 
implications of targeting cytokines through therapeutic strategies. 
 Administration of PTX in CHF patients has also demonstrated beneficial results. 
Bahrmann et al. (2004) examined the effects of PTX on LV function and circulating pro-
inflammatory cytokines in CHF patients over a 6-month period.  PTX had beneficial effects on 
LV function, O2 uptake and exercise time in patients with ischemic and hypertensive 
cardiomyopathy (Bahrmann et al., 2004).  Importantly, other clinical trials involving PTX 
treatment in CHF patients have resulted in similar outcomes (i.e. improvements in LV function, 
exercise time, and NYHA functional class; Skudicky et al., 2001; Bahrmann et al., 2004; Sliwa 
et al., 2004). Interestingly, the underlying mechanisms through which PTX downregulates TNF-
α and produces these central cardiac improvements are still not clearly understood. 
 Summary & Future Research 
It is known that CHF results in impaired peripheral vascular control (Hirai et al., 1995), 
reduced skeletal muscle BF and aerobic capacity (Musch & Terrell, 1992).  It is also known that 
less capillaries support RBC flux in CHF, impairing oxygen delivery (Richardson et al., 2003; 
McDonough et al., 2004).  CHF is associated with elevated circulating [TNF-α], which plays a 
role in both central cardiac and peripheral dysfunction (Levine et al., 1990; Finkel et al., 1992; 
Balligand et al., 1993; Reviewed by Ceconi et al., 1998). The above-mentioned perturbations 
contribute to the exercise intolerance and rapid fatigue that CHF patients experience.  Exercise 
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training is a safe and effective therapeutic strategy for both middle aged and older CHF patients 
(Antunes-Correa et al., 2011).  However, because of the severe exercise intolerance seen in many 
CHF patients drug therapies lend well to initially improving dysfunction. Direct inhibition of 
TNF-α at the receptor site via etanercept has been shown to be ineffective in CHF patients 
(Mann et al., 2004).  Conversely, improvements in LV function and reductions in plasma [TNF-
α] have been seen with PTX treatment in CHF rats and patients (Skudicky et al., 2001; 
Bahrmann et al., 2004; Sliwa et al., 2004; Guggilam et al., 2007; 2008). Unveiling the specific 
mechanism through which PTX provides these improvements is certainly important and warrants 
further investigation.  Presently, it is not know whether PTX-induced improvements in CHF 
translate to increases in skeletal muscle BF or VC in active or inactive muscles or muscle parts, 
prompting the current investigation.  
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Chapter 3 - Methods 
  Animals 
Twenty-one male Sprague Dawley rats (body mass: 492±43, age: ~6 months, Charles 
River Laboratories, Wilmington, MA) were used in the present investigation.  All rats were 
housed in accredited facilities and kept on a 12:12 light-dark cycle, with food and water provided 
ad libitum.  All procedures were approved by the Institutional Animal Care and Use Committee 
of Kansas State University and were conducted in accordance with institutional and National 
Institutes of Health guidelines.  
 Myocardial Infarction Procedure 
Myocardial infarction (MI) was induced in all rats via left main coronary artery ligation 
(Musch & Terrell, 1992).  To begin, rats were anesthetized with a 5% isoflurane (balance O2) 
mixture and intubated for mechanical ventilation with a rodent respirator (Harvard Model 680; 
Harvard Instruments, Holliston, MA) for the length of the surgical procedure.  The heart was 
accessed through a left thoracotomy in the fifth intercostal space.  The left main coronary artery 
was ligated with 6-0 silk suture approximately 1-2 mm distal to the edge of the left atrium.  The 
incision was then closed, and ampicillin (50 mg/kg i.m.) was administered to reduce risk of 
infection.  The analgesic agents bupivacaine (1.5 mg/kg s.c.) and buprenorphine (0.01-0.05 
mg/kg i.m.) were administered and isoflurane anesthesia and mechanical ventilation ceased.  All 
rats were then extubated and monitored closely for ≥6 hours for development of cardiac 
arrhythmias and signs of undue distress (i.e., labored breathing, etc.) with care administered as 
needed.  Rats were also monitored daily (i.e., appetite, weight loss/gain, gait/posture, etc.) 
consistent with an intensive 10-day post-operative plan carried out in conjunction with the 
university veterinary staff. 
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 Intervention Protocol 
21 days following the MI procedure rats were assigned randomly to either the 
experimental group (CHF+PTX, n=13), or control (CHF, n=8) group.  The CHF+PTX group 
received pentoxifylline once daily for 21 days (30 mg/kg in 0.3 ml saline i.p.) whereas the CHF 
group received saline (0.3 ml i.p.).   
 Performance Testing 
All rats were subjected to exercise performance testing on days 19 and 20 of the 21-day 
intervention period (i.e. 40-41 days following MI procedure).  Rats were first acclimatized to the 
treadmill for 5 consecutive days prior to exercise tests of endurance capacity and peak O2 uptake 
( 2OV
 peak), which were completed in random order on consecutive days.   
The endurance capacity of each rat was measured using a progressive exercise test in 
which each animal ran initially at a speed of 25 m/min up a 5% grade for 15 min.  Subsequently, 
the treadmill grade was held constant while the speed was increased incrementally by 5 m/min 
every 15 min until the rat was unable/unwilling to maintain pace with the treadmill belt despite 
manual bursts of high-pressure air aimed at the hindlimbs.  At the end of each test, exhaustion 
was confirmed by an attenuation of the rats’ righting reflex.  Our laboratory has demonstrated 
previously that time-to-exhaustion with this protocol is highly accurate and reproducible within 
each animal (Copp et al., 2009).   
2OV
 peak for each rat was determined as described previously for our laboratory (Copp et 
al., 2009).  Briefly, each rat was placed in a custom made metabolic chamber designed to fit into 
one stall on the treadmill and utilized standard techniques originally described by Brooks and 
White (1978) for determining 2OV
  and carbon dioxide (CO2) production ( 2COV
 ).  Gas analysis 
measurements were made in real-time via online CO2 and O2 analyzers (CO2: model CD-3A; O2: 
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model S-3A/I; AEI Technologies, Pittsburgh, PA) set in series. The analyzers were calibrated 
before and after each exercise test using precision-mixed gases that spanned the expected range 
of gas concentrations based on previous investigations.  Each rat ran initially in the metabolic 
chamber at a speed of 25 m/min (5% incline) for 2-3 minutes.  Subsequently, the speed of the 
treadmill was increased to 40 m/min for an additional 2-3 minutes.  Thereafter, the treadmill 
speed was increased progressively in a ramp-like manner by ~5-10 m/min every minute until the 
rat was unable or unwilling to keep pace with the treadmill belt.  2OV
 peak was recorded as the 
2OV
  at which the rat was no longer able/willing to run. Peak 2COV
  was also recorded and the 
respiratory exchange ratio (RER, 2COV
 / 2OV
 ) was calculated. Criteria for a successful test were 
the observation of a change in gait indicative of exhaustion immediately preceding the 
termination of the test (Copp et al., 2009), and/or no further increase in 2OV
  despite continued 
increases in treadmill speed.  
 Surgical Instrumentation 
The final experimental protocol was initiated immediately following the 21-day 
intervention period (i.e. ~42 days after MI procedure).  All rats were anesthetized initially with 
5% isoflurane-O2 gas mixture. The carotid artery was cannulated and a 2-French catheter-tipped 
pressure transducer (Millar Instruments, Houston, TX) was advanced into the LV for 
measurement of diastolic pressures and LV delta pressure/delta time (dp/dt). Due to technical 
complications LVEDP was not determined in 1 of the 13 CHF+PTX rats.  Upon completion of 
the measurement the transducer was removed and the carotid artery was re-cannulated with a 
catheter (PE-10 connected to PE-50, Intra-Medic polyethylene tubing, Clay Adams Brand, 
Becton, Dickinson and Company, Sparks, MD) for measurement of heart rate (HR), mean 
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arterial pressure (MAP), and arterial blood sampling.  A second catheter (PE-10 connected to 
PE-50) was placed in the caudal (tail) artery, as described previously (Musch & Terrell, 1992).  
Both catheters were tunneled subcutaneously to the dorsal aspect of the cervical region and 
exteriorized through a puncture wound in the skin.  Incisions were closed, anesthesia was 
terminated, and the animal was given >1 hour to recover. 
 Radiolabeled Microsphere Infusion 
Following the instrumentation each rat was placed on the treadmill.  The tail artery 
catheter was connected to a 1-ml plastic syringe that was connected to a Harvard 
infusion/withdrawal pump (model 907, South Nattick, MA).  The carotid artery catheter was 
connected to a pressure transducer set at the same level as the rat for continuous measurement of 
MAP and HR.  Exercise was initiated, and the speed of the treadmill was increased progressively 
during the next 30 seconds to a speed of 20 m/min (5% grade).  The rat then ran steadily for 
another 2.5 minutes.  After 3 minutes of total exercise time, blood withdrawal from the tail artery 
catheter was initiated at a rate of 0.25 ml/min.  Simultaneously, MAP and HR were measured via 
the carotid artery catheter.  The carotid artery catheter was then disconnected from the pressure 
transducer and ~0.5-0.6 X 10
6
 microspheres with 15 m diameter (
57
Co or 
85
Sr, in random order, 
Perkin Elmer Life and Analytical Sciences, Waltham, MA) were injected into the aortic arch via 
the carotid artery catheter to determine regional blood flow.  After the microsphere infusion a 
blood sample (~0.3 ml) was taken from the carotid artery catheter for measurement of blood 
gases, pH, hematocrit, and blood lactate concentrations ([lactate]).  Subsequently (~30 seconds 
after the microsphere infusion), blood withdrawal from the tail artery catheter was stopped and 
exercise was terminated.  After a >30 minute recovery period, MAP and HR were measured as 
the rat sat quietly on the treadmill. A second microsphere infusion (differently labeled from the 
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first infusion) and blood sampling procedure were then performed exactly as described above 
during exercise to determine BFs at rest.  This strategy (exercise followed by rest) minimizes the 
potential for blood loss to affect the exercise response and facilitates “resting” measurements that 
do not reflect the pre-exercise anticipatory response (Armstrong et al., 1989).   
 Determination of Morphological Characteristics, Regional BF and VC 
Following the experimental protocol rats were euthanized promptly using sodium 
pentobarbital overdose (≥100 mg/kg infused i.a. into the carotid artery catheter). The thorax was 
opened and placement of the carotid artery catheter was confirmed. The lungs were excised and 
weighed to determine lung/body mass ratio for each animal. The heart was removed; the right 
ventricle (RV) was separated from the LV and septum, and both tissues were weighed and 
normalized to each animal’s body mass. To determine LV infarct size, an incision was made 
through the interventricular septum, from the base to the apex of the LV, and a digital 
photograph of the endocardium was taken. The image was printed, and endocardial infarct 
surface area was determined by planimetry. Internal organs and individual muscles and muscle 
portions of the hindlimb were identified and excised. Upon removal, tissues were blotted, 
weighed, and placed immediately into counting vials.  
Radioactivity of each tissue was determined using a gamma scintillation counter (Packard 
Auto Gamma Spectrometer, model 5230, Downers Grove, IL). Tissue BF was then calculated 
using the reference sample method (Musch & Terrell, 1992) and expressed in ml·min
-1
·100g
-1
.  
Adequate mixing of the microspheres was confirmed for each rat by demonstrating a <15% 
difference in BF to the right and left kidney and/or to the right and left hindlimb musculature. 
VC was calculated by normalizing BF to MAP and expressed as ml·min
-1
·100g
-1
·mmHg
-1 
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 Blood Sample and Cytokine Analysis 
Pre-PTX and post-PTX administration blood samples were taken from the sub-orbital 
plexus using a glass capillary pipette. This sampling method was implemented to avoid acute 
elevation of cytokine concentrations post-surgical instrumentation. Pre-PTX blood samples were 
taken prior to group assignment, and post-PTX blood samples were taken prior to catheterization 
on the day of the final experimental protocol.  Approximately 0.8 ml of blood was drawn into 
heparinized sample tubes, and centrifuged at 6000 g at 4°C for 6 minutes, plasma was extracted 
and frozen immediately at -80°C for later analysis of plasma cytokine concentrations.  
Circulating [TNF-α] was quantified in the plasma by using a commercially available rat TNF-α 
enzyme-linked immunosorbent assay (ELISA) kit according to manufacturer instructions 
(Abcam, Cambridge, MA). Due to technical complications [TNF-α] in 1 of the 13 CHF+PTX 
rats was not determined. 
 Statistical Analysis 
Cardiac morphological and hemodynamic measurements were compared using unpaired 
Student’s t-tests.  Plasma [TNF- α] variance was compared using a post hoc F-test.  All other 
data were compared within (rest vs. exercise) and between (CHF vs. CHF+PTX) groups using 
mixed 2-way ANOVAs and Student-Newman-Keuls post hoc tests where appropriate.  
Significance was set at p<0.05 and values are expressed as mean ± SEM. 
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Chapter 4 - Results 
 Effects of PTX on plasma [TNF-α] 
Due to large sample variability in plasma [TNF-α] among rats the large absolute 
differences between CHF and CHF+PTX rats came close but did not reach statistical 
significance (p=0.052). However, the CHF+PTX group demonstrated significantly less variance 
in post-intervention plasma [TNF-α] compared with CHF (p<0.05, Figure 1). 
 Effects of PTX on Cardiac Indices and Exercise Performance 
MI size and hemodynamic and morphological indices of cardiac function for CHF and 
CHF+PTX rats are presented in Table 1.  The LVEDP/MI size ratio was significantly lower in 
CHF+PTX compared with CHF (p<0.05, Figure 2). There was no difference in endurance 
capacity between groups (CHF: 18±5, CHF+PTX: 19±2 min, p>0.05). 2OV
 peak was not 
different (p>0.05) between CHF (64±7, RER: 1.08± 0.03) and CHF+PTX (66±3 ml O2·kg
-1
·min
1
, 
RER:1.02±0.02) groups. 
 Effects of PTX on HR, MAP, arterial [O2], saturation, and [lactate] 
The effects of PTX on resting and exercising HR and MAP are displayed in Figure 3.  
CHF+PTX rats had higher MAP at rest and during exercise compared to CHF (p<0.05 for both).  
HR was not different between groups at rest but was greater in CHF+PTX compared to CHF rats 
during exercise (p<0.05). There were no differences in resting (CHF: 95±2, CHF+PTX: 97±1%, 
p>0.05) or exercising (CHF: 95±2, CHF+PTX: 96±1%, p>0.05) arterial O2 saturation (and, 
therefore, calculated arterial [O2]) between groups.  Blood [lactate] was not different between 
groups at rest (CHF: 1.1±0.4, CHF+PTX: 0.9±0.1 mmol/L) or during exercising (CHF: 4.5±1.5, 
CHF+PTX: 4.7±0.7 mmol/L). 
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 Effects of PTX on hindlimb BF and VC at rest and during exercise 
There were no differences in resting total hindlimb BF or VC between CHF and 
CHF+PTX rats (Figure 4).  Moreover, there were no differences in resting BF or VC to any 
individual hindlimb muscle or muscle part between groups (Table 2).  In contrast, exercising 
total hindlimb skeletal muscle BF and VC were significantly elevated in CHF+PTX compared to 
CHF rats (Figure 4). Specifically, exercising BF was higher in 21 of 28 and VC was higher in 11 
of 28 individual hindlimb muscles or muscle parts in CHF+PTX compared to CHF rats with no 
apparent muscle fiber-type composition or function specificity (Table 3).  
 Effect of PTX on renal and splanchnic BF and VC at rest and during exercise 
Renal and splanchnic BF and VC values are presented in Table 4. Blood flow to the 
adrenals, spleen, and large intestine were higher at rest in CHF+PTX rats compared to CHF 
(p<0.05) whereas only resting adrenal and splenic VC was higher in CHF+PTX rats (p<0.05). 
There were no differences in renal or splanchnic organ BF and VC during exercise between 
groups (p>0.05). 
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Chapter 5 - Discussion 
The principal novel finding of the present investigation is that PTX administration (30 
mg·kg
-1
·day
-1
 for 21 days) in CHF+PTX rats elevated hindlimb skeletal muscle BF and, 
therefore, O2 delivery during submaximal treadmill exercise compared to CHF.  The significant 
improvements in O2 delivery were associated with enhanced cardiac function, increased VC, and 
elevated systemic driving pressure for bulk O2 delivery (i.e. increased MAP). However, despite 
the significant cardiovascular improvements PTX administration had no effects on endurance 
capacity or 2OV
 peak. 
 Mechanisms of PTX-induced BF elevations  
Whole-body exercise prompts sympathetically-mediated increases in cardiac output and 
peripheral blood flow redistribution toward working skeletal muscle.  Within active skeletal 
muscle vascular beds blood flow increases via mechanical, humoral, and metabolic vasomotor 
control signals.  CHF patients and animals evidence lower skeletal muscle blood flow and O2 
delivery for a given level of exercise compared to healthy subjects consequent to lower cardiac 
output, exaggerated sympathetic vasoconstriction and impaired vascular endothelial function 
(Reviewed by Poole et al., 2012).  Importantly, elevations in TNF-α have been implicated, in 
part, as one mechanism underlying each of the above-mentioned perturbations (Cunnion et al., 
1989; Reviewed by Ceconi et al., 1998) and it has been shown that plasma [TNF-α] correlates 
positively with CHF severity (Levine et al., 1990).  
Previous studies have shown that TNF-α administration in cancer patients can induce 
cardiac enlargement and pulmonary congestion, as well as reduce myocardial contractility, 
leading to cardiomyopathy (Hegewisch et al., 1990; Finkel et al., 1992). In the present 
investigation blockade of TNF-α production in CHF+PTX rats with the phosphodiesterase 
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inhibitor PTX increased cardiac contractility (i.e. increased LV dp/dt) and lowered LVEDP and 
the lung/body mass ratio (suggesting less pulmonary congestion consequent to improvement in 
LV contractile function). These marked improvements in cardiac function were evident despite 
similar MI size between the CHF and CHF+PTX group and are consistent with previous 
investigations (Sliwa et al., 2004; Guggilam et al., 2007; 2008).  
 CHF-induced cardiac dysfunction, particularly during exercise, challenges the ability of 
the cardiovascular system to regulate MAP. In this regard, the higher resting and exercising 
MAP values observed herein following PTX administration are similar to that observed in 
healthy rats (Pfeifer et al., 2001; Ferguson et al., 2013) and likely reflect improvements in 
cardiac function as discussed above. Interestingly, at rest it appears that PTX-induced elevations 
in MAP are facilitated by increased SV, as HR and organ and hindlimb muscle VC (i.e. the 
inverse of systemic vascular resistance) were unchanged. Conversely, during exercise the 21% 
higher MAP is consistent with increases in both SV and HR (given HR increased only 8%), 
which occurred despite significant increases in VC (and therefore lower systemic vascular 
resistance). Additionally, the elevated exercising HR response seen in CHF+PTX rats is 
consistent with reversal of the chronotropic incompetence associated with CHF. This reversal 
has also been achieved through exercise training (Musch et al., 1989). 
 PTX administration in CHF+PTX rats increased exercising hindlimb skeletal muscle BF 
( 38%) and, therefore, O2 delivery compared to CHF. This increase occurred concomitant with a 
higher cardiac output (as opposed to peripheral redistribution, as suggested by similar or 
increased kidney and splanchnic organ BFs between groups), elevated systemic driving pressure 
for bulk O2 delivery (i.e. higher MAP), as well as modified peripheral vascular control (i.e. 18% 
higher VC). In regards to the latter, TNF-α participates in functional derangement of endothelial 
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cells, which includes activation of iNOS (Reviewed by Ceconi et al., 1998), formation of 
adhesive molecules (Reviewed by Ceconi et al., 1998; Suschek et al., 1993), and decreased 
endothelial nitric oxide synthase (eNOS) mRNA due to its increased rate of degradation (Blum 
& Miller, 2001). Stosić-Grujicić et al. (2001) demonstrated that PTX administration results in 
reduced local iNOS expression in intraislet and endothelial cells. This suggests that PTX 
administration could be increasing exercising BF through reductions in iNOS, thus lessening the 
systemic inflammatory response, and enhancing local NO-mediated vasodilation via increased 
eNOS expression and/or function. Moreover, PTX administration reduces renal sympathetic 
nerve activity (RSNA) (Guggilam et al., 2007; 2008) consistent with the notion that PTX 
administration may be exerting a central effect, whereby BF is increased due to less 
sympathetically-meditated vasoconstriction. Further investigation into the effects of PTX on NO 
bioavailability, reactive O2 species (ROS) regulation, and sympathetic nerve activity during 
exercise may elucidate the specific mechanisms of PTX-induced BF elevations in CHF+PTX rats 
evident in the present investigation. Given the lack of muscle fiber-type specific exercising BF 
and VC increases found herein and the fiber-type specificity of vasomotor signals including NO 
(Hirai et al., 1994), sympathetic vasoconstriction (Behnke et al., 2011), and functional 
sympatholysis (Thomas et al., 1994), it is likely that PTX modified multiple vascular control 
pathways. 
 Clinical Implications 
In the present investigation PTX administration increased hindlimb skeletal muscle BF 
and VC but did not change exercise endurance capacity or 2OV
 peak between groups. Those 
exercise performance values are consistent with severe CHF (Musch et al., 2002). However, the 
improved indices of cardiac function following PTX administration in the CHF+PTX group 
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more closely resemble moderate CHF (Diederich et al., 2002). The relatively short 21 day PTX 
treatment period could potentially play a role in the lack of improvement in exercise 
performance, similar to the delayed reversal of impaired vasodilation seen in CHF patients post-
heart transplantation (Sinoway et al., 1988).  However, the present data are also consistent with 
the fact that PTX administration improves LV function but not exercise performance in CHF 
patients (Skudicky et al., 2001; Bahrmann et al., 2004; Sliwa et al., 2004) and suggests that PTX 
may not improve the ability of the active skeletal muscle to utilize the increased O2 delivery 
during exercise. For example, alterations in capillary geometry (Xu et al., 1998), fewer 
capillaries supporting red blood cell flux at rest and during contractions (Kindig et al., 1999; 
Richardson et al., 2003), a reduced capillary-muscle fiber ratio (Xu et al., 1998; Wüst et al., 
2012), and altered microvascular O2 pressure kinetics (Diederich et al., 2002) as well as intrinsic 
skeletal muscle abnormalities including lower oxidative enzyme activity (Arnolda et al., 1991; 
Delp et al., 1997), mitochondrial dysfunction (Wüst et al., 2012) and impaired excitation-
contractile function (Poole-Wilson et al., 1988; Musch et al., 2002; Helwig et al., 2003; Perreault 
et al., 2003;) have been reported in CHF. The absence of PTX-induced improvements in any of 
these mechanisms may potentially explain the lack of improvements in exercise performance 
despite higher skeletal muscle BF in CHF+PTX rats found herein. For this reason, further 
investigation into the effects of PTX on capillary hemodynamics and microvascular O2 pressure 
kinetics during muscle contraction, as well as PTX administration combined with therapies that 
may ameliorate structural and functional vascular and metabolic derangements (i.e. exercise 
training) and/or reduce the O2 cost of exercise (i.e. nitrate supplementation, Jones et al., 2012), 
may prove most efficacious in improving exercise tolerance and quality of life in CHF patients. 
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 Experimental Considerations 
In the present investigation PTX administration reduced [TNF-α] variance in CHF+PTX 
rats, and resulted in close-to-significant reductions in [TNF-α] (~70% , p=0.052), compared 
with CHF. Guggilam et al.  (2007; 2008) reported lower tissue-bound TNF-α expression in the 
LV and paraventricular nucleus, as well as circulating [TNF-α] following PTX administration.  It 
is important to note that our investigation differed from Guggilam et al. (2007; 2008) in that the 
present sample size was smaller, blood sampling was done at rest not in response to an endotoxin 
or stress stimulus, and 21 days were allowed (post-MI procedure) for development of CHF prior 
to the intervention (Fishbein et al., 1978). This 21-day time period may account for initial 
elevations in plasma [TNF-α] seen in pre-PTX blood sampling (Guggilam et al., 2007). 
Furthermore, post-PTX plasma [TNF-α] values in CHF+PTX rats resembled closely pre-PTX 
administration values. Conversely, in CHF rats plasma [TNF-α] appear to increase and become 
more variable over the same time period. Importantly, our present data is consistent with the 
complex nature of the TNF-α system previously described by Ferrari et al. (1995) as well as 
several studies where PTX administration in CHF patients did not reduce circulating [TNF-α] 
(Skudicky et al., 2001; Bahrmann et al., 2004).  The complexity of TNF-α bioassays and the 
effects of soluble TNF-α receptors (sTNF-Rs) on TNF-α activity as well as the conditions of our 
sampling are potential explanations for [TNF-α] variability found herein. The present PTX dose 
(30 mg·kg
-1
·day
-1
) as well as administration route (i.p.) was chosen because of the successful 
results (i.e. reductions in RSNA, ROS, [TNF-α], and improved LV function) seen both centrally 
and peripherally by Guggilam et al. (2007; 2008). Although those authors administered PTX for 
a 5-week period, it is noteworthy that we were able to see major cardiovascular effects of the 
drug after our 21-day administration protocol. 
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 Summary and Conclusion 
The present study is the first to investigate the effects of PTX administration on skeletal 
muscle BF and VC at rest and during submaximal treadmill exercise in CHF rats. PTX 
administration (30 mg·kg
-1
·day
-1
 for 21 days) improved LV function and elevated skeletal muscle 
BF and VC in CHF rats. These improvements were associated with PTX-induced elevations in 
MAP (similar to values observed in healthy rats) and reductions in plasma [TNF-α] variance 
compared with CHF. Although the specific mechanisms responsible for the increases in skeletal 
muscle BF and VC remain unclear, the improvements in both cardiac and peripheral vasculature 
function have crucial implications for CHF patients. 
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Table 1.  Morphological and hemodynamic characteristics of CHF and CHF+PTX rats. 
 
 
 
 
 
 
MI, myocardial infarct size; LVEDP, left ventricular end diastolic pressure; LV dp/dt, left 
ventricular delta pressure/delta time. CHF: n=8; CHF+PTX: n=13 (LVEDP and LV dp/dt reflect 
n=12) *p<0.05 versus CHF rats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHF CHF+PTX 
MI, % 37±4 37±3 
LVEDP, mmHg 24±3 16±2* 
RV/body mass, mg/g 0.77±0.08 0.72±0.04 
Lung/body mass, mg/g 7.7±1.2 5.2±0.6* 
LV dp/dt, mmHg/s 5663±502 6783±277* 
23 
 
Table 2. Effects of PTX on resting blood flow (ml·min
-1
·100 g
-1
) and vascular conductance (VC, ml·min
-
1
·100 g
-1
·mmHg
-1
) to the individual muscles or muscle parts of the rat. 
 Blood flow  VC 
 CHF CHF+PTX  CHF CHF+PTX 
Ankle extensors      
Soleus 72±14 111±19  0.72±0.17 0.92±0.17 
Plantaris 13±4 11±2  0.12±0.04 0.09±0.01 
Gastrocnemius, red 21±6 41±10  0.22±0.07 0.34±0.09 
Gastrocnemius, white 9±2 9±1  0.08±0.02 0.07±0.01 
Gastrocnemius, mixed 8±2 13±2  0.08±0.02 0.11±0.02 
Tibialis posterior 11±2 14±2  0.11±0.02 0.12±0.01 
Flexor digitorum longus 12±2 19±3  0.12±0.02 0.15±0.03 
Flexor halicus longus 9±1 10±1  0.09±0.03 0.08±0.01 
      
Ankle flexors      
Tibialis anterior, red 22±11 24±6  0.19±0.10 0.20±0.05 
Tibialis anterior, white 13±5 14±2  0.12±0.05 0.11±0.01 
Extensor digitorum longus 10±2 19±3  0.10±0.02 0.08±0.01 
Peroneals 12±2 15±2  0.12±0.02 0.13±0.02 
      
Knee extensors      
Vastus intermedius 46±11 82±15  0.47±0.12 0.66±0.11 
Vastus medialis 12±3 17±2  0.12±0.03 0.14±0.02 
Vastus lateralis, red 27±12 43±8  0.26±0.11 0.35±0.06 
Vastus lateralis, white 10±3 10±1  0.10±0.03 0.08±0.01 
Vastus lateralis, mixed 12±4 13±1  0.11±0.03 0.11±0.01 
Rectus femoris, red 17±6 24±5  0.15±0.06 0.18±0.04 
Rectus femoris, white 10±2 13±2  0.09±0.02 0.10±0.01 
      
Knee flexors      
Biceps femoris anterior 6±1 8±1  0.06±0.01 0.06±0.01 
Biceps femoris posterior 7±2 10±2  0.07±0.02 0.08±0.02 
Semitendinosus 11±3 15±3  0.10±0.03 0.12±0.02 
Semimembranosus, red 11±3 12±3  0.11±0.03 0.10±0.02 
Semimembranosus, white 9±2 8±1  0.09±0.02 0.07±0.01 
      
Hip adductors      
Adductor longus 106±17 135±12  0.99±0.17 1.09±0.10 
Adductor magnus & brevis 11±3 12±2  0.10±0.03 0.10±0.02 
Gracilis 11±3 16±3  0.11±0.03 0.13±0.03 
Pectinius 18±4 25±3  0.15±0.04 0.20±0.03 
Data are mean±SEM. CHF: n=8; CHF+PTX: n=13. 
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Table 3.  Exercising individual hindlimb skeletal muscle and muscle part blood flow (ml·min
-1
·100g
-1
) and 
VC (ml·min
-1
·100g
-1
·mmHg) for CHF and CHF+PTX groups. 
 Blood flow  VC 
 CHF CHF+PTX  CHF CHF+PTX 
Ankle extensors      
Soleus 257±25 258±20  2.33±0.24 2.00±0.15 
Plantaris 148±23 209±17*  1.36±0.21 1.62±0.12 
Gastrocnemius, red 298±22 361±56  2.69±0.20 2.79±0.41 
Gastrocnemius, white 36±10 45±4  0.36±0.12 0.35±0.03 
Gastrocnemius, mixed 118±10 156±14*  1.08±0.11 2.21±0.10 
Tibialis posterior 95±17 114±19  0.89±0.19 0.89±0.14 
Flexor digitorum longus 54±17 108±19*  0.54±0.19 0.85±0.15* 
Flexor halicus longus 50±10 88±7*  0.47±0.10 0.68±0.05* 
      
Ankle flexors      
Tibialis anterior, red 251±29 304±22*  2.27±0.27 2.36±0.17 
Tibialis anterior, white 81±12 112±7*  0.72±0.08 0.87±0.05* 
Extensor digitorum longus 38±6 62±6*  0.36±0.06 0.48±0.05* 
Peroneals 101±11 141±15*  0.91±0.09 1.09±0.11 
      
Knee extensors      
Vastus intermedius 301±23 353±25*  2.71±0.22 2.76±0.21 
Vastus medialis 138±20 182±15*  1.24±0.19 1.41±0.11 
Vastus lateralis, red 238±32 361±29*  2.13±0.26 2.80±0.23* 
Vastus lateralis, white 13±3 23±2*  0.12±0.03 0.18±0.02* 
Vastus lateralis, mixed 116±12 141±12*  1.04±0.12 1.10±0.11 
Rectus femoris, red 220±24 247±18  1.96±0.20 1.93±0.14 
Rectus femoris, white 91±10 98±6  0.82±0.09 0.78±0.05 
      
Knee flexors      
Biceps femoris, anterior 15±3 28±4*  0.14±0.03 0.22±0.03* 
Biceps femoris, posterior 67±9 83±7*  0.60±0.08 0.65±0.05 
Semitendinosus 33±6 60±5*  0.30±0.05 0.47±0.04* 
Semimembranosus, red 92±16 126±16*  0.84±0.15 0.98±0.12 
Semimembranosus, white 16±3 32±5*  0.14±0.03 0.25±0.04* 
      
Hip adductors      
Adductor longus 254±40 297±27  2.31±0.36 2.29±0.19 
Adductor magnus & brevis 64±13 92±11*  0.57±0.11 0.71±0.08 
Gracilis 21±5 57±8*  0.15±0.05 0.45±0.06* 
Pectinius 27±7 59±9*  0.25±0.07  0.46±0.07* 
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(Table 3 caption) 
Data are mean±SEM.  CHF: n=8; CHF+PTX: n=13.  *p<0.05 versus CHF. 
Within CHF 24, and within CHF+PTX 28, of 28 hindlimb muscles and muscle parts 
demonstrated elevated exercising blood flow and VC above rest (p<0.05) (exceptions: gracilis, 
pectinius, white portions of the semimembranosus and vastus lateralis for CHF group) 
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Table 4. Renal and splanchnic organ blood flow (ml·min
-1
·100g
-1
) and VC (ml·min
-1
·100g
-1
·mmHg) at rest and during exercise for 
CHF and CHF+PTX groups. 
 At rest  During exercise 
 Blood flow  VC  Blood flow  VC 
 CHF CHF+PTX  CHF CHF+PTX  CHF CHF+PTX  CHF CHF+PTX 
Right kidney 542±30 576±38  5.26±0.36 4.68±0.33  379±56 350±48  2.87±0.42 2.67±0.35 
Left kidney 534±32 556±33  5.19±0.35 4.53±0.30  373±61 341±48  2.72±0.42 2.59±0.34 
Stomach 108±18 139±20  0.89±0.16 1.14±0.18  53±12 61±9  0.35±0.08 0.46±0.06 
Adrenals 431±59 683±62*  4.04±0.72 5.52±0.51*  267±52 388±50  1.91±0.36 2.97±0.36 
Spleen 254±46 398±51*  2.09±0.23 3.19±0.39*  62±16 78±18  0.43±0.13 0.59±0.13 
Pancreas 139±21 166±25  1.19±0.19 1.35±0.19  93±26 113±23  0.75±0.18 0.86±0.16 
Sm. intestine 377±60 460±41  3.11±0.57 3.77±0.37  220±42 238±24  1.50±0.30 1.83±0.17 
Lg. intestine 168±25 223±24*  1.41±0.16 1.82±0.20  112±31 120±19  0.75±0.20 0.92±0.14 
Liver
1
 16±3 27±7  0.16±0.04 0.22±0.05  14±3 25±5  0.10±0.02 0.19±0.04 
 
Data are mean±SEM. 1Denotes arterial not portal blood flow.  CHF: n=8; CHF+PTX: n=13.  *p<0.05 versus CHF.
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Figure 1. Effects of PTX administration on plasma [TNF-α] pre and post PTX administration. 
CHF: n=8; CHF+PTX: n=12.  Data are mean±SEM. Absolute difference in post intervention 
plasma [TNF-α] did not reach statistical significance (p=0.052). † F-test revealed a significant 
reduction in [TNF-α] variance in CHF+PTX rats. 
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Figure 2. Effects of PTX administration on LVEDP/MI ratio.  CHF: n=8; CHF+PTX n=12.  Data 
are mean±SEM. *p<0.05 versus CHF. 
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Figure 3.  Effects of PTX administration on MAP and HR. MAP and HR measured at rest and 
during submaximal treadmill exercise. Within CHF and CHF+PTX conditions exercise MAP and 
HR were significantly different from rest (p<0.05). Systolic/diastolic pressure is depicted within 
MAP bars and are all significantly different between CHF and CHF+PTX groups. CHF: n=8; 
CHF+PTX: n=13. Data are mean±SEM. *p<0.05 versus CHF. 
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Figure 4. Total hindlimb muscle BF and VC at rest and during exercise for CHF and CHF+PTX 
rats. Within CHF and CHF+PTX groups exercising BF and VC were significantly different 
(p<0.05) from rest.  CHF: n=8; CHF+PTX: n=13.  Data are mean±SEM. *p<0.05 versus CHF. 
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